Company Overview
Bliss GVS Pharma Ltd. is an Indian pharmaceutical company specializing in suppositories, pessaries, anti-malarial drugs, women's healthcare products, and specialty formulations. The company exports products to more than 80 countries and has a strong presence in emerging markets.
Bliss GVS Pharma Screener Table
| Parameter | Value |
|---|---|
| CMP (Approx.) | ₹381 |
| Market Capitalization | ₹4,030 Cr |
| Stock P/E | 36.9 |
| Dividend Yield | 0.33% |
| Revenue (TTM) | ₹868 Cr |
| Net Profit (TTM) | ₹109 Cr |
| EPS (TTM) | ₹10.19 |
| 52-Week High | ₹381 |
| 52-Week Low | ₹118 |
| Debt Level | Moderate |
| Industry | Pharmaceuticals |
| Export Presence | 80+ Countries |
Figures are approximate and subject to market changes.
Financial Performance
| Financial Year | Revenue (₹ Cr) | Net Profit (₹ Cr) |
|---|---|---|
| FY23 | 752 | 85 |
| FY24 | 770 | 51 |
| FY25 | 810 | 69 |
| TTM | 868 | 109 |
Revenue and profitability have improved steadily over the last few years, while FY26 earnings growth has accelerated significantly.
Key Strengths
✅ Global presence across emerging markets
✅ Leading manufacturer of suppositories and pessaries
✅ Diversified product portfolio with 400+ products
✅ Improving profit margins and earnings growth
✅ Strong pharmaceutical export business
✅ Regulatory approvals from multiple international agencies
Key Risks
⚠ Dependence on international markets
⚠ Currency fluctuation risks
⚠ Regulatory inspections can affect operations
⚠ Higher valuation after recent stock rally
⚠ Competitive pharmaceutical industry
Growth Triggers
| Growth Driver | Impact |
|---|---|
| Expansion in Africa & Latin America | Revenue Growth |
| New Product Launches | Margin Expansion |
| USFDA & Global Approvals | Export Opportunity |
| Women's Healthcare Portfolio | Long-Term Growth |
| Specialty Pharma Products | Higher Profitability |
Investment Scorecard
| Factor | Rating |
|---|---|
| Sales Growth | ⭐⭐⭐⭐☆ |
| Profit Growth | ⭐⭐⭐⭐☆ |
| Balance Sheet | ⭐⭐⭐⭐☆ |
| Export Business | ⭐⭐⭐⭐⭐ |
| Valuation | ⭐⭐⭐☆☆ |
| Long-Term Potential | ⭐⭐⭐⭐☆ |
Verdict
Bliss GVS Pharma is a mid-cap pharmaceutical company with strong export exposure, improving earnings, and a niche leadership position in specialty dosage forms. Long-term investors may consider tracking the stock for continued growth in exports and specialty pharma segments, while monitoring valuation levels after its sharp run-up.
0 Comments